Sept. 17, 2012
-- The Pharmaceutical industry is constantly undergoinging changes. In the past pharmaceutical companies used to develop products internally. That has changed. In-house resources are often quickly exhausted. For many years pharma companies have been under pressure because drugs are going off patent. They look for ways to stay competitive. It takes $+1.5B and many R&D years for a new drug to enter the market. Patient recruitment and medical personnel account for nearly 70 per cent of the clinical costs that are required to bring a drug to market. To better cope with these issues pharmaceutical companies are increasingly utilizing CROs. Global outsourced R&D expenditure is projected to continue to increase over the next years. In this presentation, Salto Partners takes a look at two outsourcing models utilized by Fortune 500 companies. It discusses the pros and cons of either approach. The presentation ends with 5 top do's and don’ts managing projects successfully with CROs.
About PMI's Pharmaceutical Community of Practice
The Pharmaceutical CoP (http://pharma.vc.pmi.org/
) offers you a forum for the professional exchange of ideas on a variety of topics related to managing drug, biotech, and medical device projects from early-stage R&D to marketing, and beyond.
Experts and practitioners from various areas of the industry share their knowledge and experience. Presenters at PMI's Annual Seminars & Symposium and other Pharmaceutical CoP-sponsored events explore modern practices, techniques, and tools providing invaluable information. Many concepts and ideas, along with lessons learned, produce practical ideas and solutions to take back to the job. In addition, you can add valuable new perspectives for implementing project management from those managing projects in other industries.